Locoregional Therapy for Intrahepatic Cholangiocarcinoma

Cancers (Basel). 2023 Apr 20;15(8):2384. doi: 10.3390/cancers15082384.

Abstract

Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis, and surgical resection (SR) offers the only potential for cure. Unfortunately, only a small proportion of patients are eligible for resection due to locally advanced or metastatic disease. Locoregional therapies (LRT) are often used in unresectable liver-only or liver-dominant ICC. This review explores the role of these therapies in the treatment of ICC, including radiofrequency ablation (RFA), microwave ablation (MWA), transarterial chemoembolization (TACE), transarterial radioembolization (TARE), external beam radiotherapy (EBRT), stereotactic body radiotherapy (SBRT), hepatic arterial infusion (HAI) of chemotherapy, irreversible electroporation (IE), and brachytherapy. A search of the current literature was performed to examine types of LRT currently used in the treatment of ICC. We examined patient selection, technique, and outcomes of each type. Overall, LRTs are well-tolerated in the treatment of ICC and are effective in improving overall survival (OS) in this patient population. Further studies are needed to reduce bias from heterogenous patient populations and small sample sizes, as well as to determine whether certain LRTs are superior to others and to examine optimal treatment selection.

Keywords: external beam radiotherapy; hepatic arterial infusion; intrahepatic cholangiocarcinoma; irreversible electroporation; locoregional therapy; microwave ablation; radiofrequency ablation; stereotactic body radiotherapy; transarterial chemoembolization; transarterial radioembolization.

Publication types

  • Review

Grants and funding

This research received no external funding.